T
1.20
0.00 (0.00%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Tevogen Bio Holdings Inc. | - | - |
AIStockmoo Score
-1.4
| Analyst Consensus | 0.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -4.0 |
| Average | -1.38 |
|
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (“CD8+ CTLs” or “CTLs”), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 91.35% |
| % Held by Institutions | 1.47% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| China Universal Asset Management Co., Ltd. | 31 Dec 2024 | 37,117 |
| 52 Weeks Range | ||
| Median | 10.00 (733.33%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| D. Boral Capital | 11 Mar 2025 | 10.00 (733.33%) | Buy | 1.07 |
| 04 Mar 2025 | 10.00 (733.33%) | Buy | 1.27 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |